Q-omics provides the consensus-scored TSEN2P1 profile across patient tissues and cancer cell-line models. TSEN2P1 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TSEN2P1 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, TSEN2P1 RNA expression shows 5,878 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, COAD, and STAD as cancer lineages where TSEN2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSEN2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSEN2P1 survival associations across molecular data types. TSEN2P1 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSEN2P1 RNA expression–survival associations across cancer types. High TSEN2P1 expression shows unfavorable associations in LUSC, BLCA, SKCM, PCPG and KIRP. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for TSEN2P1 RNA expression.
This table summarizes TSEN2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TSEN2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSEN2P1 shows higher tumor expression in COAD. The COAD box plot shows higher TSEN2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .026).
This table shows molecular features associated with TSEN2P1 in patient tissues and cancer cell lines. In patient samples, TSEN2P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
